| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1479-666X(05)80047-2 |
| P698 | PubMed publication ID | 16353857 |
| P2093 | author name string | Mason RC | |
| Forshaw MJ | |||
| Gossage JA | |||
| P2860 | cites work | Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis | Q24797571 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography | Q28354052 | ||
| Reporting results of cancer treatment | Q29620070 | ||
| Treatment of esophageal carcinoma | Q33808179 | ||
| Multidisciplinary approach to esophageal and gastric cancer | Q33932046 | ||
| Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer | Q34190498 | ||
| Cancer of the esophagogastric junction | Q34348338 | ||
| Recent changes in the epidemiology of esophageal cancer | Q34466585 | ||
| Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies | Q34466604 | ||
| Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia | Q34548295 | ||
| Multimodality therapy for resectable cancer of the thoracic esophagus | Q34568031 | ||
| A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer | Q34593949 | ||
| Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer | Q34631393 | ||
| Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus | Q35204863 | ||
| Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer | Q35363348 | ||
| Neoadjuvant therapy for oesophagogastric cancer | Q35762516 | ||
| Postoperative mortality following oesophagectomy and problems in reporting its rate. | Q35852383 | ||
| Induction chemotherapy in the treatment of patients with carcinoma of the esophagus | Q71633210 | ||
| Influence of clinician workload and patterns of treatment on survival from breast cancer | Q72226515 | ||
| The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus | Q72341899 | ||
| Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy | Q72691179 | ||
| Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer | Q73183799 | ||
| Is esophageal cancer a surgical disease? | Q73339022 | ||
| Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial | Q73624732 | ||
| Cervical esophagogastric anastomosis: results following esophagectomy for carcinoma | Q73687870 | ||
| Hospital volume and hospital mortality for esophagectomy | Q73746434 | ||
| Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials | Q73756660 | ||
| Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer | Q73851845 | ||
| Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer | Q74784866 | ||
| Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy | Q75405260 | ||
| Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer | Q77318936 | ||
| Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer | Q77443192 | ||
| Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer | Q77738544 | ||
| Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy | Q77833246 | ||
| Does preoperative chemotherapy cause adverse effects on the perioperative course of patients undergoing esophagectomy for carcinoma? | Q77991747 | ||
| Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma | Q78016040 | ||
| Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities | Q78167068 | ||
| Evaluation of Response to Neoadjuvant Therapy by Quantitative 2-Deoxy-2-[F]Fluoro-D-Glucose with Positron Emission Tomography in Patients with Esophageal Cancer | Q79138203 | ||
| Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation | Q95807545 | ||
| Molecular biology of upper gastrointestinal malignancies | Q35857426 | ||
| Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer | Q35895058 | ||
| The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma | Q36080278 | ||
| Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland | Q36596331 | ||
| New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology | Q36617794 | ||
| The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction | Q36644282 | ||
| Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen | Q36646204 | ||
| Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer | Q36648325 | ||
| Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study | Q37339195 | ||
| Estimates of the worldwide mortality from 25 cancers in 1990. | Q39358305 | ||
| Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival | Q39405901 | ||
| NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy | Q40577988 | ||
| Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. | Q40667282 | ||
| Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma | Q40943503 | ||
| Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction | Q41188853 | ||
| Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus | Q41543455 | ||
| Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial | Q42285544 | ||
| Early impact of centralization of oesophageal cancer surgery services. | Q42639274 | ||
| Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging | Q43641822 | ||
| Treatment outcomes of resected esophageal cancer | Q43920736 | ||
| Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer | Q43956924 | ||
| Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead? | Q43961330 | ||
| Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer | Q43983613 | ||
| Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial | Q44017893 | ||
| Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer | Q44028630 | ||
| Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer | Q44158871 | ||
| Outcomes after esophagectomy: a ten-year prospective cohort | Q44284360 | ||
| Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. | Q44298526 | ||
| Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods | Q44663842 | ||
| Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma | Q44695858 | ||
| Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction | Q44908374 | ||
| 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma | Q45073453 | ||
| Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study | Q45154773 | ||
| Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity | Q45222787 | ||
| CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study | Q45714364 | ||
| Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? | Q47282777 | ||
| Weight gain as an indicator of response to chemotherapy for oesophageal carcinoma | Q47362274 | ||
| Esophageal surgery at the end of the millennium | Q47755190 | ||
| CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus | Q50080671 | ||
| Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. | Q50697375 | ||
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. | Q54104558 | ||
| Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma | Q57546312 | ||
| Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group | Q67526968 | ||
| Medical audit, cancer registration, and survival in ovarian cancer | Q68293405 | ||
| Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037) | Q68965886 | ||
| Effect of surgical experience on the results of resection for oesophageal carcinoma | Q69587169 | ||
| Treatment of carcinoma of the esophagus or cardia | Q69757301 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 373-82, 422 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Journal of the Royal College of Surgeons of Edinburgh | Q15752473 |
| P1476 | title | Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation | |
| P478 | volume | 3 |
| Q37156639 | Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance? |
| Q33755139 | Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis |
| Q41789442 | PET: other thoracic malignancies |
| Q44143001 | Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel |
| Q36874277 | Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review |
| Q64890442 | Substernal long segment left colon interposition for oesophageal replacement. |
| Q36593709 | Total adventitial resection of the cardia: 'optimal local resection' for tumours of the oesophagogastric junction |
Search more.